The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Dulaglutide, a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor agonist , https://bookmarkinglive.com/story22715528/both-medications-and-nad-a-integrated-approach-to-general-wellness